Gencurix Inc.
KOSDAQ 229000.KQ
Gencurix Inc. Free Cash Flow Yield on January 14, 2025: -54.09%
-
Gencurix Inc. 52-week high Free Cash Flow Yield is -14.97% on January 17, 2024, which is 72.32% above the current Free Cash Flow Yield.
-
Gencurix Inc. 52-week low Free Cash Flow Yield is -78.59% on December 09, 2024, which is -45.32% below the current Free Cash Flow Yield.
-
Gencurix Inc. average Free Cash Flow Yield for the last 52 weeks is -33.24%.
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
| CEO | Sung-Rai Cho |
| IPO Date | April 5, 2017 |
| Location | South Korea |
| Headquarters | Hanhwa Bizmetro |
| Employees | 69 |
| Sector | Health Care |
| Industries | |
Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email